DxTerity is a company dedicated to expanding the use and utility of genomic testing in human healthcare. We believe that significant transformations in managing and curing disease are possible by understanding the genetic mechanisms underlying the disease. Furthermore, we believe that Genomic Information will be invaluable to Medical Practitioners in not only identifying disease but in accurately characterizing the progression, and leading to its successful treatment. Today, despite its immense promise, complex genomic testing is simply too expensive for widespread adoption in clinical practice, and too complex for most labs to perform. We have solved these problems through a revolutionary technology that allows direct from sample testing of complex gene expression signatures.

This DxDirect™ methodology brings unprecedented simplicity and flexibility in delivering Complex Genomic Information from a patient sample.

DxDirect:

• handles signatures from 5 to 100 genes in a single tube
• accommodates a diversity of sample targets from mRNA, SNPs and DNA copy number
• produces highly quantitative output preserving relative expression among targets
• integrates with existing instrumentation
• follows an easy 5 step procedure, from a single tube in less than 1 hour

Our objective is to deliver this powerful genomic testing technology into routine medical care across a broad range of diseases and chronic conditions.

We are committed to make this advancement in genomic medicine widely available through DxTerity Diagnostics’ products, and through Clinical and Research Partners who share our passion for making complex genomic testing a simple, fast and affordable part of routine medical care.

Our Promise…

If it says DxTerity, it’s

• Simple – fewer steps and lower complexity means accessibility for more labs
• Fast – multiplex results the same day for better service and greater efficiency
• Affordable – less labor, fewer reagents and smaller sample size defines the new economy complex genomic testing